Figure 3.

Meta-analysis of the risk of glucose variability for microvascular complications stratified by treatment arms of ACCORD and VADT. Hazard ratios (95% CI) in each study were estimated based on fully adjusted Model-3. Fixed-effect meta-analysis and inverse variance weighted method was used. Differential risks of glucose variability were assessed by assessing an interaction between glucose variability and treatment groups. For composite outcome^#, P value of interaction is 0.07 and 0.24 for CV and ARV respectively. For nephropathy*, P values for interactions were 0.06 and 0.08 for CV and ARV respectively. For retinopathy⁺, P values for interactions were 0.06 and 0.30 for CV and ARV, respectively.